ZA202209896B - Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof - Google Patents

Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof

Info

Publication number
ZA202209896B
ZA202209896B ZA2022/09896A ZA202209896A ZA202209896B ZA 202209896 B ZA202209896 B ZA 202209896B ZA 2022/09896 A ZA2022/09896 A ZA 2022/09896A ZA 202209896 A ZA202209896 A ZA 202209896A ZA 202209896 B ZA202209896 B ZA 202209896B
Authority
ZA
South Africa
Prior art keywords
inducing
protein degradation
sulfonamide
effect
pharmaceutical use
Prior art date
Application number
ZA2022/09896A
Other languages
English (en)
Inventor
Ohba Kiyomi
Niwa Yasuki
Matsudaira Tetsuji
Hamada Maiko
Yamazaki Ryuta
IBUKI Tatsuya
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77199607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA202209896(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of ZA202209896B publication Critical patent/ZA202209896B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2022/09896A 2020-02-06 2022-09-05 Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof ZA202209896B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020019227 2020-02-06
PCT/JP2021/004231 WO2021157684A1 (ja) 2020-02-06 2021-02-05 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Publications (1)

Publication Number Publication Date
ZA202209896B true ZA202209896B (en) 2025-12-17

Family

ID=77199607

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/09896A ZA202209896B (en) 2020-02-06 2022-09-05 Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof

Country Status (14)

Country Link
US (3) US12102641B2 (https=)
EP (1) EP4105220A4 (https=)
JP (3) JP7419406B2 (https=)
KR (1) KR20220139912A (https=)
CN (1) CN115087658B (https=)
AR (1) AR121275A1 (https=)
AU (1) AU2021215623A1 (https=)
BR (1) BR112022014889A2 (https=)
CA (1) CA3168824C (https=)
IL (1) IL295041A (https=)
MX (1) MX2022009700A (https=)
TW (1) TWI887352B (https=)
WO (1) WO2021157684A1 (https=)
ZA (1) ZA202209896B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
JP2022123408A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123894A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP2022123407A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123893A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP7852736B2 (ja) * 2022-10-28 2026-04-28 株式会社村田製作所 電子部品および電子部品の実装構造
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN120865239B (zh) * 2025-09-25 2025-12-12 深圳大学 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
JP2801500B2 (ja) 1993-07-02 1998-09-21 株式会社トクヤマ Ｎ−アルコキシカルボニルアミノ酸の製造方法
CN1109037C (zh) 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
CN109503618A (zh) * 2017-09-14 2019-03-22 成都海创药业有限公司 一种brd4抑制剂
EP3723757A4 (en) 2017-12-14 2021-08-18 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE TYPE DEGRADATION AGENTS RECRUITING DCAF15
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
EP3819305A4 (en) * 2018-07-04 2022-04-06 Mitsubishi Tanabe Pharma Corporation AMIDE COMPOUND WITH BET PROTEOLYSIS-INDUCING ACTIVITY AND MEDICAL USE THEREOF
JP7140273B2 (ja) 2019-04-09 2022-09-21 株式会社村田製作所 電池
JP7419406B2 (ja) * 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Also Published As

Publication number Publication date
KR20220139912A (ko) 2022-10-17
US20230146717A1 (en) 2023-05-11
TWI887352B (zh) 2025-06-21
MX2022009700A (es) 2022-09-07
US12102641B2 (en) 2024-10-01
WO2021157684A1 (ja) 2021-08-12
EP4105220A4 (en) 2024-02-21
IL295041A (en) 2022-09-01
AU2021215623A1 (en) 2022-08-25
CA3168824C (en) 2024-10-22
TW202140498A (zh) 2021-11-01
US20230364105A1 (en) 2023-11-16
AR121275A1 (es) 2022-05-04
CN115087658B (zh) 2025-02-28
JPWO2021157684A1 (https=) 2021-08-12
JP2024041888A (ja) 2024-03-27
JP7419406B2 (ja) 2024-01-22
CA3168824A1 (en) 2021-08-12
EP4105220A1 (en) 2022-12-21
JP2025122015A (ja) 2025-08-20
CN115087658A (zh) 2022-09-20
US11890288B2 (en) 2024-02-06
JP7681737B2 (ja) 2025-05-22
BR112022014889A2 (pt) 2022-09-20
US20240390387A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
ZA202209896B (en) Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
NZ777871A (en) Small molecule modulators of il-17
PH12020551762A1 (en) Peptide macrocycles against acinetobacter baumannii
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
JOP20200154B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
JOP20210172B1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
BR112019024016A2 (pt) amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
EA201300420A1 (ru) Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
PH12020551772A1 (en) Oxo-substituted compound
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
BR112023024746A2 (pt) Composto inibidor de iodotironina desiodase tipo 2, e, composição farmacêutica